Save time and jump to the most important pieces.
Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
10/8/2024 | $44.50 → $48.00 | Neutral | Citigroup | |
10/3/2024 | $33.00 | Overweight → Underweight | Morgan Stanley | |
3/5/2024 | Buy → Hold | Argus | ||
2/13/2024 | Sell → Hold | Societe Generale | ||
1/23/2024 | $105.00 → $86.50 | Buy → Sell | UBS | |
1/23/2024 | Sell | UBS | ||
1/23/2024 | Neutral | UBS | ||
11/16/2023 | $95.00 | Neutral | Redburn Atlantic |
SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)
SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)
SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)
Citigroup reiterated coverage of Altria with a rating of Neutral and set a new price target of $48.00 from $44.50 previously
Morgan Stanley downgraded British American Tobacco from Overweight to Underweight and set a new price target of $33.00
Argus downgraded Philip Morris International from Buy to Hold
Altria Group, Inc. (NYSE:MO) today reports our 2024 third-quarter and nine-months business results and reaffirms our guidance for 2024 full-year adjusted diluted earnings per share (EPS). "Altria delivered outstanding results in the third quarter," said Billy Gifford, Altria's Chief Executive Officer. "The smokeable products segment delivered solid operating companies income growth behind the resilience of Marlboro, and in the oral tobacco products segment, our MST brands continued to drive profitability while on! maintained momentum in the marketplace. We also continued to reward shareholders through a growing dividend and share repurchases while making investments in pursuit of our Visio
Third-Quarter Reported Diluted EPS grew 49.2% to $1.97, Adjusted Diluted EPS increased by 14.4% to $1.91 and grew by 18.0% excluding currency Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2024 third-quarter and first nine-months results.1 "In the third quarter, we delivered exceptionally strong performance, with record quarterly net revenues and earnings per share," said Jacek Olczak, Chief Executive Officer. "This reflects excellent momentum across all regions and categories, with a reacceleration in IQOS adjusted in-market sales growth, strong ZYN volumes, and resilient combustible performance." "As a result of our strong year-to-date delivery, we
CCAA Plan Includes PMI's Canadian Affiliate RBH, Deconsolidated Since 2019; If RBH Reconsolidated, Expected to be Incremental to Key PMI Financial Metrics Regulatory News: Philip Morris International Inc. (PMI) has been informed by its deconsolidated Canadian affiliate, Rothmans, Benson & Hedges Inc. (RBH), that the court-appointed mediator and monitor in RBH's Companies' Creditors Arrangement Act (CCAA) proceeding filed a proposed plan of compromise and arrangement (Proposed Plan) outlining certain terms of a comprehensive resolution of tobacco product-related claims and litigation in Canada against RBH and its affiliates. The court-appointed mediator and monitors also filed substantiall
Pharmaceutical customers and patients to benefit from the combined design, development and manufacturing services of Vectura and Phillips Medisize Phillips Medisize to add a market-leading position in inhalation combination product development to its existing suite of drug delivery device design capabilities Vectura employees to join a large global company, dedicated to improving patients' lives through innovative products and world class quality and manufacturing capabilities Molex, a parent to Phillips Medisize, a leader in the design, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices, announced that, through its affiliate Molex
Philip Morris International Inc. (PMI) (NYSE:PM) is pleased to announce the appointment of Christos Harpantidis to the position of Senior Vice President, External Affairs effective May 1, 2024. In his new role, Mr. Harpantidis will report to the company's CEO, Jacek Olczak. "Christos is an experienced business leader with a proven track record of engaging society on the benefits of tobacco harm reduction and risk-proportionate regulation for smoke-free products," said CEO Jacek Olczak. "He has been instrumental in building our smoke-free business in Greece and the South East Europe Area as we evolve away from cigarettes. I'm looking forward to working with Christos and excited to see what
In honor of Women's History Month and in advance of International Women's Day, investment and partnership support female economic empowerment and equality through entrepreneurship Today, Philip Morris International (PMI) (NYSE:PM) announces the launch of an extended partnership via its U.S. business to support female empowerment with a record-setting $5 million investment in the Women's Business Development Council (WBDC), a 501(c)(3) charitable organization dedicated to providing tools and resources to help women entrepreneurs thrive in business throughout Connecticut. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202403048002
4 - ALTRIA GROUP, INC. (0000764180) (Issuer)
4 - ALTRIA GROUP, INC. (0000764180) (Issuer)
8-K - Philip Morris International Inc. (0001413329) (Filer)
6-K - British American Tobacco p.l.c. (0001303523) (Filer)
6-K - British American Tobacco p.l.c. (0001303523) (Filer)
JP Morgan analyst Jared Dinges maintains Philip Morris Intl (NYSE:PM) with a Overweight and raises the price target from $110 to $125.
As of July 25, 2024, three stocks in the consumer staples sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro. Here's the latest list of major overbought players in this sector. Unilever plc (NYSE:UL) On July 25, Unilever reported quarterly adjusted earnings of $1
4 - Philip Morris International Inc. (0001413329) (Issuer)
4 - Philip Morris International Inc. (0001413329) (Issuer)
4 - Philip Morris International Inc. (0001413329) (Issuer)
Philip Morris International affiliate, Swedish Match, earned first-ever FDA authorization for a modified risk marketing claim and now is the first to achieve an FDA renewal PMI affiliates have secured 13 of the 16 modified risk tobacco product (MRTP) authorizations that the FDA has granted, demonstrating the company's commitment to a smoke-free future. The U.S. Food and Drug Administration (FDA) authorized a renewal of a risk modification order submitted by Swedish Match USA, Inc. (Swedish Match), an affiliate of Philip Morris International, Inc. (PMI) (NYSE:PM), for eight General snus products. As part of the authorization, the agency granted use of the modified risk claim to reach
Altria Group, Inc. (NYSE:MO) today reports our 2024 third-quarter and nine-months business results and reaffirms our guidance for 2024 full-year adjusted diluted earnings per share (EPS). "Altria delivered outstanding results in the third quarter," said Billy Gifford, Altria's Chief Executive Officer. "The smokeable products segment delivered solid operating companies income growth behind the resilience of Marlboro, and in the oral tobacco products segment, our MST brands continued to drive profitability while on! maintained momentum in the marketplace. We also continued to reward shareholders through a growing dividend and share repurchases while making investments in pursuit of our Visio
Third-Quarter Reported Diluted EPS grew 49.2% to $1.97, Adjusted Diluted EPS increased by 14.4% to $1.91 and grew by 18.0% excluding currency Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2024 third-quarter and first nine-months results.1 "In the third quarter, we delivered exceptionally strong performance, with record quarterly net revenues and earnings per share," said Jacek Olczak, Chief Executive Officer. "This reflects excellent momentum across all regions and categories, with a reacceleration in IQOS adjusted in-market sales growth, strong ZYN volumes, and resilient combustible performance." "As a result of our strong year-to-date delivery, we